2m 2m 2m 2m 2m 2m 2m
Editas Medicine (EDIT)
NASDAQ
$2.83+$0.05 (+1.62%)
Price as of Jun 03, 2026 7:41 PM EDT- $531.0MMarket Cap
- 54.95%1-Year Change
- BiotechnologyIndustry
Editas Medicine (EDIT)
$2.83+$0.05 (+1.62%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 40.5M +25.39% | 32.3M -58.64% | 78.1M +296.32% | 19.7M -22.83% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 40.5M +25.39% | 32.3M -58.64% | 78.1M +296.32% | 19.7M -22.83% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -90.0M -54.85% | -199.2M +12.16% | -177.7M +1.54% | -175.0M +22.77% | |
Depreciation and Amortization Expense | 5.3M -9.16% | 5.8M -4.21% | 6.1M -4.31% | 6.3M +25.41% | |
Total Operating Expenses | 200.5M -29.26% | 283.5M +14.62% | 247.3M +0.67% | 245.7M +12.33% | |
Operating Profit | -160.0M -36.29% | -251.2M +48.45% | -169.2M -25.12% | -225.9M +16.98% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -6.2M +189.99% | -2.1M N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | -6.2M +189.99% | -2.1M N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | -50,000 -100.36% | 14.1M -11.92% | 16.0M +189.27% | 5.5M +756.83% | |
Income before Taxes | -160.0M -36.29% | -251.2M +48.45% | -169.2M -23.25% | -220.4M +14.51% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | 3.8M N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -160.1M -32.49% | -237.1M +54.74% | -153.2M -30.49% | -220.4M +14.51% | |
Net Income from Continuing Operations Applicable to Common | -160.1M -32.49% | -237.1M +54.74% | -153.2M -30.49% | -220.4M +15.11% | |
Basic EPS and Net Income | -1.80 -37.50% | -2.88 +42.57% | -2.02 -37.07% | -3.21 +12.63% | |
Diluted EPS and Net Income | -1.80 -37.50% | -2.88 +42.57% | -2.02 -37.07% | -3.21 +13.43% | |
Basic Weighted Average Shares | 88.7M +7.78% | 82.3M +8.39% | 76.0M +10.63% | 68.7M +1.55% | |
Diluted Weighted Average Shares | 88.7M +7.78% | 82.3M +8.39% | 76.0M +10.63% | 68.7M +1.55% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 146.6M +11.48% | 131.5M +6.38% | 123.7M -12.63% | 141.5M -30.46% | |
Short-Term Investments | 0 -100.00% | 138.4M -30.63% | 199.5M -1.62% | 202.8M -31.58% | |
Cash and Cash Equivalents and Short-Term Investments | 146.6M -45.67% | 269.9M -16.46% | 323.1M -6.15% | 344.3M -31.12% | |
Total Current Assets | 163.9M -43.35% | 289.3M -15.11% | 340.8M -4.46% | 356.8M -29.68% | |
Accumulated Depreciation | 28.4M -10.41% | 31.6M +20.52% | 26.3M +21.99% | 21.5M +38.81% | |
Property and Plant and Equipment and Net | 3.5M -75.57% | 14.5M +20.49% | 12.0M -22.72% | 15.6M -9.05% | |
Total Long-Term Assets | 3.0M -43.02% | 5.2M -39.18% | 8.6M +63.49% | 5.3M -22.87% | |
Total Assets | 186.5M -45.39% | 341.6M -31.57% | 499.2M -2.95% | 514.3M -24.08% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 5.0M 0.00% | 5.0M N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 46.2M -40.12% | 77.2M +22.16% | 63.2M +5.17% | 60.1M +28.21% | |
Total Long-Term Debt | 53.6M +2.23% | 52.4M N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 2.8M -8.37% | 3.1M +70.67% | 1.8M -98.08% | 93.5M +240.11% | |
Total Liabilities | 159.2M -23.19% | 207.3M +38.16% | 150.1M -2.33% | 153.6M +24.06% | |
Retained Earnings | -1.6B +10.90% | -1.5B +19.25% | -1.2B +14.21% | -1.1B +25.70% | |
Total Stockholders Equity | 27.3M -79.68% | 134.3M -61.54% | 349.1M -3.21% | 360.7M -34.85% | |
Total Shares Outstanding | 97.9M +18.29% | 82.7M +1.18% | 81.8M +18.77% | 68.8M +0.60% | |
Cash Flow | |||||
Cash from Operating Activities | -165.2M -21.42% | -210.3M +59.09% | -132.2M -25.47% | -177.3M +8.27% | |
Capital Expenditures | 607,000 -93.12% | 8.8M +87.03% | 4.7M +14.59% | 4.1M -48.38% | |
Cash from Investing Activities | 138.7M -14.48% | 162.1M +4,445.91% | -3.7M -103.27% | 114.1M +309.43% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 40.5M -27.77% | 56.0M -52.54% | 118.0M +9,093.07% | 1.3M -99.54% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -394.89% -49.19% | -777.22% +258.90% | -216.56% -81.11% | -1,146.26% +51.59% | |
Return on Assets | -60.61% +7.47% | -56.40% +86.53% | -30.24% -18.26% | -36.99% +20.11% | |
Return on Equity | -198.14% +101.98% | -98.10% +127.22% | -43.17% -10.46% | -48.22% +18.63% | |
Revenue Growth | 25.39% +143.31% | -58.64% -119.79% | 296.32% +1,397.88% | -22.83% -68.22% | |
Current Ratio | 3.54 -5.40% | 3.75 -30.51% | 5.39 -9.16% | 5.94 -45.15% | |
Cash Ratio | 3.17 +86.17% | 1.70 -12.92% | 1.96 -16.92% | 2.35 -45.76% | |
Debt-to-Equity Ratio | 2.15 +402.13% | 0.43 N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.31 +86.91% | 0.17 N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow